Vor Bio, RemeGen succeed in trial for telitacicept in China

[Hand inserts a molecule into DNA.]
Natali_Mis/iStock via Getty Images

Shares of Vor Bio (NASDAQ:VOR [https://seekingalpha.com/symbol/VOR]) rose after it reported that its partner, RemeGen (OTCPK:REGMF), met the main goal in a late stage trial conducted in China on the use of telitacicept for Sjögren's disease treatment.

In June, Vor Bio and RemeGen entered into a licensing agreement that allows Vor Bio to develop telitacicept globally, except for China, Hong Kong, Macau, and Taiwan.

The trial in China showed an improvement in disease activity across 12 different domains compared to a placebo.

Telitacicept has shown a positive safety profile throughout the study [https://seekingalpha.com/pr/20199433-telitacicept-achieved-primary-endpoint-in-phase-3-clinical-study-for-primary-sjogrens-disease].

The shares of the company are up 25% today.

Looking ahead, RemeGen plans to submit a marketing application to the National Medical Products Administration in China for the treatment. If approved, this will mark telitacicept's fourth indication in China.

MORE ON VOR BIOPHARMA

* Vor Biopharma: Not So Sure About This Surge, And Do Mind The Warrants [https://seekingalpha.com/article/4799973-vor-biopharma-not-so-sure-about-this-surge-and-do-mind-the-warrants]
* Vor Bio appoints Sandy Mahatme as CFO [https://seekingalpha.com/news/4466599-vor-bio-appoints-sandy-mahatme-as-cfo]
* Vor Bio surges after private placement, licensing deal [https://seekingalpha.com/news/4462943-vor-bio-stock-surges-private-placement]
* Seeking Alpha’s Quant Rating on Vor Biopharma [https://seekingalpha.com/symbol/VOR/ratings/quant-ratings]
* Historical earnings data for Vor Biopharma [https://seekingalpha.com/symbol/VOR/earnings]